{"title":"3.COVID-19疫苗(ChAdOx1-S[重组])(VaxzevriaTM肌肉注射)安全性措施的经验:重点关注上市后早期警惕","authors":"Masako Shimoo, H. Kato, T. Tokimoto","doi":"10.3820/jjpe.27.79","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14576,"journal":{"name":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","volume":"165 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"3 . Experiences in Safety Measures for COVID‒19 Vaccine(ChAdOx1‒S [recombinant])(VaxzevriaTM Intramuscular Injection): Focusing on the Early Post-marketing Phase Vigilance\",\"authors\":\"Masako Shimoo, H. Kato, T. Tokimoto\",\"doi\":\"10.3820/jjpe.27.79\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14576,\"journal\":{\"name\":\"Japanese Journal of Pharmacoepidemiology\\\\/yakuzai Ekigaku\",\"volume\":\"165 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Pharmacoepidemiology\\\\/yakuzai Ekigaku\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3820/jjpe.27.79\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3820/jjpe.27.79","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
3 . Experiences in Safety Measures for COVID‒19 Vaccine(ChAdOx1‒S [recombinant])(VaxzevriaTM Intramuscular Injection): Focusing on the Early Post-marketing Phase Vigilance